By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...

Breast cancer is the second leading malignant disease in females worldwide. Over decades of research, breast cancer classification by molecular subtypes has ...

As genetic and biomarker tests become more common, so do new therapies that target specific tumor types and may lead to ...

People assigned female at birth have a predisposition for migraines, especially in adolescence and around menopause. Find a ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer involves tumor cells that test positive for hormone ...

Progesterone is the other major sex hormone, in addition to estrogen, produced by the female body. Progesterone is involved in regulating the female menstrual cycle. Hormone receptor-positive breast ...

For many women, finding out that they have breast cancer is the worst news they can receive. Even worse news is if the breast cancer is termed “triple-negative,” which is ...